<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>25 Lymphoma I: Hodgkin lymphoma (Hodgkin's disease)</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-24-myeloma.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 62.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 25 of 40</span>
                    </div>
                    <a href="haematology-26-lymphoma-II-non-hodgkin-lymphoma.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">25 Lymphoma I: Hodgkin lymphoma (Hodgkin's disease)</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="lymphoma-intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>Lymphoma is a neoplastic proliferation of lymphoid cells originating in lymph nodes or other lymphoid tissue. It is a heterogeneous group of disorders, divided into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Approximately 200 new cases are diagnosed each year per million population, with a ratio of NHL/HL of approximately 6:1; the incidence is rising.</p>
                    </div>
                </section>

                <section id="aetiology-epidemiology" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Aetiology and epidemiology</span>
                    </h2>
                    <div class="content-card">
                        <p>Hodgkin lymphoma is more prevalent in males than females (M/F ratio 1.5-2.0:1) and has a peak incidence in age range of 15-40 years. The cause is not known, but Epstein-Barr virus (EBV) infection may be a cofactor.</p>
                    </div>
                </section>

                <section id="histological-classification" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Histological classification</span>
                    </h2>
                    <div class="content-card">
                        <p>This is well defined and of prognostic significance (see p. 72). Reed-Sternberg (RS) cells are characteristic of HL (Fig. 25.1) but their exact cell of origin is unknown, and RS cells are usually outnumbered by a non-malignant reactive infiltrate of eosinophils, plasma cells, lymphocytes and histiocytes. HL is of B-cell origin.</p>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-067-1.jpg" alt="Fig. 25.1 Lymph node biopsy showing a multinucleate Reed-Sternberg cell, characteristic of Hodgkin lymphoma." class="content-image">
                            <figcaption>Fig. 25.1 Hodgkin lymphoma: lymph node biopsy showing a Reed-Sternberg cell (multinucleate cell).</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Enlarged, painless lymphadenopathy (typically cervical) is the characteristic presentation. The nodes often fluctuate in size, and alcohol ingestion may precipitate pain.</li>
                            <li>Hepatic and splenic enlargement may occur.</li>
                            <li>Systemic symptoms (fever, weight loss, pruritus and drenching night sweats) occur in 25%.</li>
                            <li>Extranodal disease is uncommon but lung, CNS, skin and bone involvement may occur.</li>
                            <li>Infection caused by defective cell-mediated/humoral immunity (Fig. 25.3).</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-067-2.jpg" alt="Fig. 25.2 Photograph showing a skin rash characteristic of varicella zoster (shingles) infection in a patient with Hodgkin lymphoma." class="content-image">
                            <figcaption>Fig. 25.2 Hodgkin lymphoma: varicella zoster infection.</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="laboratory-features" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Laboratory features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Anaemia (normochromic, normocytic).</li>
                            <li>Leucocytosis (occasionally eosinophilia).</li>
                            <li>Leuco-erythroblastic blood film.</li>
                            <li>Raised erythrocyte sedimentation rate (ESR), raised lactate dehydrogenase (LDH)—useful as prognostic marker and for monitoring response—and abnormal liver function tests.</li>
                        </ul>
                    </div>
                </section>

                <section id="staging" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                        <span class="heading-text">Staging</span>
                    </h2>
                    <div class="content-card">
                        <p>Staging influences both treatment and prognosis. Clinical staging with careful physical examination is followed by cervical thoracic, abdominal and pelvic CT or MRI scanning (Fig. 25.3). Bone marrow aspirate and trephine are performed to detect marrow involvement. The most commonly used staging system is the Cotswold Classification (Fig. 25.4).</p>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-068-1.jpg" alt="Fig. 25.3 Two images for Hodgkin lymphoma staging: (a) a chest X-ray and (b) a CT scan, both showing hilar lymphadenopathy." class="content-image">
                            <figcaption>Fig. 25.3 Hodgkin lymphoma: (a) chest Xray and (b) CT scan showing hilar lymphadenopathy.</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-068-2.jpg" alt="Fig. 25.4 Diagram illustrating the clinical features and staging of Hodgkin lymphoma (Stages I-IV), including criteria for A/B symptoms and bulky disease." class="content-image">
                            <figcaption>Fig. 25.4 Hodgkin lymphoma: clinical features and staging. Stage I: involvement of a single lymph node region or structure; stage II: involvement of two or more lymph node regions on the same side of the diaphragm; stage III: involvement of lymph node regions or structures on both sides of the diaphragm; stage IV: involvement of other organs, e.g. liver, bone marrow, CNS. A: no symptoms; B: fever, night sweats, weight loss >10% in preceding 6 months; X: bulky disease: >1/3 widening of mediastinum; 10 cm max dimension of nodal mass; E: extralymphoid disease (e.g. in lung, skin).</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="treatment" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <p>This depends principally on stage.</p>
                        <ul>
                            <li>Radiotherapy alone may be used for patients with clinical or pathological stage IA or IIA disease with favourable histology.</li>
                            <li>Advanced (stages IB, IIB, III and IV) HD should be treated with combination chemotherapy (CCT) using one of the standard regimes (e.g. six cycles of Adriamycin, bleomycin, vinblastine and dacarbazine, ABVD).</li>
                            <li>For bulky mediastinal disease, especially common in young females with nodular sclerosing HL, chemotherapy followed by deep X-ray therapy (DXT) (combined modality therapy) may be given and local DXT may be needed for other sites of bulky or resistant disease.</li>
                        </ul>
                        <p>For complications of treatment see Chapter 39.</p>
                    </div>
                </section>

                <section id="relapsed-disease" class="content-section" aria-labelledby="section-heading-8">
                    <h2 id="section-heading-8" class="section-heading">
                        <span class="heading-text">Relapsed disease</span>
                    </h2>
                    <div class="content-card">
                        <p>Patients who relapse following DXT alone generally have a very good response to CCT (&gt;80% complete remission (CR) rate). Patients initially treated with chemotherapy who relapse after a remission lasting more than 1 year are likely to achieve CR again, and up to 50% may be cured with CCT. However, patients relapsing within 1 year of initial therapy, or failing to achieve complete remission, have a poorer prognosis and should be considered for high-dose therapy with stem cell rescue (see Chapter 38).</p>
                    </div>
                </section>

                <section id="prognosis" class="content-section" aria-labelledby="section-heading-9">
                    <h2 id="section-heading-9" class="section-heading">
                        <span class="heading-text">Prognosis</span>
                    </h2>
                    <div class="content-card">
                        <p>Stage is of paramount importance for HL. While &gt;90% of stage I and II may be cured, the rate falls progressively to 50% of stage IV patients. Older patients generally do less well, as do those with lymphocyte-depleted histology.</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-24-myeloma.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 62.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 25 of 40</span>
                    </div>
                    <a href="haematology-26-lymphoma-II-non-hodgkin-lymphoma.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>